# Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

> **NCT04588480** · PHASE4 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 160 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** BNT162b2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04588480
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2021-11-25
- **Final completion:** 2021-11-25
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588480, "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04588480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*